Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will ...
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in ...
Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...
For more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has been pioneering in ...
(Reuters) -Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. (Reporting by Sneha S K; editing by Tasim Zahid) The FDA Just Added 9 ...
TRENTON, N.J. (AP) -- Drugmaker Merck & Co., a pioneer in AIDS research, is licensing two experimental HIV drugs from other companies and advancing one of its own into mid-stage patient testing. Merck ...
Merck & Co. said a late-stage study of its proposed oral doravirine/islatravir regimen met its key goals in adults with HIV-1 infection who haven't previously taken antiretroviral treatments. Merck on ...
Investigational DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority to BIC/FTC/TAF in a Phase 3 clinical trial in treatment-naïve adults with HIV-1 infection The company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results